Fluidigm Corporation has begun direct service to customers in China.
Fig 1: Fluidigm's 96.96 Dynamic Array.
Through the establishment of a wholly-owned Fluidigm subsidiary in China in late January 2012, officially known as Fluidigm (Shanghai) Instrument Technology Co., Ltd. or 富鲁达(上海)仪器科技有限公司, Fluidigm will improve services to its Chinese customer base and expects to rapidly build a strong presence in that country’s burgeoning life science research community.
“The establishment of our China subsidiary in this rapidly growing nation is an especially important commercial development for Fluidigm. We believe China will be an important growth driver for Fluidigm in 2012 and into the future,” said Gajus Worthington, president and chief executive officer of Fluidigm. “China is aggressively pursuing research in therapeutic stem cells and single-cell genomics. Customers in various Chinese universities, hospitals and government-sponsored laboratories are conducting world-class research in these areas of global importance and they need world-class tools to help them achieve their objectives. We believe Fluidigm nanofluidic technology brings the world’s most advanced single-cell and stem-cell solutions available in the world to the Chinese life science research community. We want to help our customers move forward in these critical areas of research as quickly as possible,” Worthington concluded.
“Over the years, we have sold and installed more than 20 instruments in China. Those systems are helping our customers conduct single-cell research, prepare samples for targeted sequencing experiments, and ensure the quality and safety of China’s food supply. This is a good beginning and we hope to contribute more capabilities to the Chinese research community in the future,” said Joanna Jiang, general manager of Fluidigm China. “While we now have a direct presence in China, we are a small company and will continue to work with our distribution partners to ensure that we can meet the needs of our customers throughout China’s vast geography.”
Fig 1: Fluidigm's 96.96 Dynamic Array microfluidic chip conducts 9,216 biology experiments at one time. (Photo: Business Wire)
Fluidigm is the creator and world’s leading supplier of integrated fluidic circuits. Fluidigm microfluidic chips, systems, assays and other reagents enable genetic analysis that in many instances were previously impractical. To help its customers achieve and exploit advances in life science research, agricultural biotechnology, or Ag-Bio, and molecular diagnostics, Fluidigm provides robust systems that deliver high throughput and simpler workflows at decreased costs. Fluidigm microfluidic systems overcome many of the limitations of conventional laboratory systems by integrating a vast number of fluidic components onto a single microfabricated chip. Fluidigm technology enables its customers to perform and measure thousands of sophisticated biochemical reactions on samples smaller than the content of a single cell, while utilizing minute volumes of reagents and samples. Similarly, for next generation DNA sequencing, Fluidigm systems enable rapid preparation of multiple samples in parallel at low cost.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our plans, objectives, expectations and strategies for our China subsidiary, business and related future growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that could materially affect future results include, but are not limited to, our ability to expand our customer base, introduce new applications and successfully compete in our markets and industry, risks relating to international operations, global economic conditions, and the other risk factors contained in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q. These forward-looking statements speak only as of the date hereof. Fluidigm Corporation disclaims any obligation to update these forward-looking statements.
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips, assays and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems, including eight different commercial chips, to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.